Press Release Archive
Press Releases
September 2020
09.09.2020 Covid-19 Vaccines Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2 09.08.2020 Vaccines Biopharma Leaders Unite To Stand With Science 09.03.2020 Finance Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020
August 2020
08.20.2020 Covid-19 Research Vaccines Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19 08.17.2020 Medicines Pfizer Statement on Lyrica (Pregabalin) Patent Infringement in Japan 08.12.2020 Research Vaccines Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARSCoV-2 in Nature 08.07.2020 Covid-19 Partnerships Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19 08.06.2020 Finance Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020 08.06.2020 Responsibility Pfizer signs on to The Hispanic Promise further strengthening its ties and commitment to Hispanics in the workplace 08.05.2020 Medicines The Bristol-Myers Squibb-Pfizer Alliance is pleased with the U.S. District Court decision to uphold both the composition of matter (COM) patent (US 6,967,208) and formulation patent (US 9,326,945) covering Eliquis®. 08.05.2020 Medicines LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer 08.05.2020 Vaccines Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.